In the wake of the reauthorization of the Generic Drug User Fee Amendments (GDUFA), the FDA has updated its guidance for prior approval supplements (PAS) and amendments for abbreviated new drug applications (ANDA) under GDUFA III.
Source: Drug Industry Daily